IRIS
VIOLA, Anna
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 1.548
NA - Nord America 1.271
AS - Asia 1.027
SA - Sud America 342
AF - Africa 25
Continente sconosciuto - Info sul continente non disponibili 2
OC - Oceania 2
Totale 4.217
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.222
RU - Federazione Russa 626
SG - Singapore 533
BR - Brasile 304
IE - Irlanda 242
IT - Italia 218
SE - Svezia 192
CN - Cina 191
HK - Hong Kong 174
DE - Germania 64
FR - Francia 44
VN - Vietnam 39
GB - Regno Unito 34
CA - Canada 29
PL - Polonia 28
FI - Finlandia 24
IN - India 24
AT - Austria 21
NL - Olanda 16
MX - Messico 15
AR - Argentina 12
JP - Giappone 12
BD - Bangladesh 9
ZA - Sudafrica 9
EC - Ecuador 8
ES - Italia 6
PK - Pakistan 6
TR - Turchia 6
BE - Belgio 5
ID - Indonesia 5
IQ - Iraq 5
JO - Giordania 5
LT - Lituania 5
MA - Marocco 5
PY - Paraguay 5
VE - Venezuela 4
AE - Emirati Arabi Uniti 3
CH - Svizzera 3
CL - Cile 3
CO - Colombia 3
CZ - Repubblica Ceca 3
DO - Repubblica Dominicana 3
DZ - Algeria 3
KE - Kenya 3
KZ - Kazakistan 3
NO - Norvegia 3
UA - Ucraina 3
UZ - Uzbekistan 3
BY - Bielorussia 2
EE - Estonia 2
NZ - Nuova Zelanda 2
PE - Perù 2
RO - Romania 2
RS - Serbia 2
SN - Senegal 2
AO - Angola 1
AZ - Azerbaigian 1
BG - Bulgaria 1
BW - Botswana 1
EU - Europa 1
GE - Georgia 1
GR - Grecia 1
HU - Ungheria 1
IL - Israele 1
IR - Iran 1
LK - Sri Lanka 1
NI - Nicaragua 1
PH - Filippine 1
SA - Arabia Saudita 1
SY - Repubblica araba siriana 1
TN - Tunisia 1
TT - Trinidad e Tobago 1
TW - Taiwan 1
UY - Uruguay 1
XK - ???statistics.table.value.countryCode.XK??? 1
Totale 4.217
Salva come PNG Salva come JPEG
Città #
Moscow 343
Singapore 245
Dublin 240
Ashburn 224
Hong Kong 174
Chandler 169
Dallas 139
Nyköping 94
Beijing 62
Messina 57
Los Angeles 49
Princeton 37
Medford 33
Munich 30
São Paulo 25
Des Moines 24
New York 21
Redondo Beach 20
Buffalo 19
Seattle 15
The Dalles 14
Vienna 14
Ann Arbor 13
Ho Chi Minh City 13
London 13
Milan 13
Hanoi 12
Catania 11
Denver 11
Frankfurt am Main 11
Stockholm 11
Tokyo 11
Warsaw 11
Atlanta 10
Brooklyn 10
Lauterbourg 10
Nuremberg 10
Amsterdam 9
Chennai 9
Jinan 9
Rome 9
Curitiba 8
Mexico City 8
Montreal 8
Council Bluffs 7
Dearborn 7
Lappeenranta 7
Porto Alegre 7
Rio de Janeiro 7
Santa Clara 7
Turku 7
Boston 6
Campinas 6
Changsha 6
Jacksonville 6
Nanjing 6
Pozzuolo Martesana 6
San Francisco 6
Tianjin 6
Toronto 6
Turin 6
Wilmington 6
Amman 5
Belo Horizonte 5
Brussels 5
Düsseldorf 5
Hebei 5
Helsinki 5
Johannesburg 5
Orem 5
Phoenix 5
Brasília 4
Cagliari 4
Chicago 4
Guayaquil 4
Haikou 4
Hangzhou 4
Jakarta 4
Manchester 4
Mumbai 4
Palermo 4
Pelotas 4
Pune 4
San Jose 4
Shenyang 4
Vitória da Conquista 4
Zhengzhou 4
Aracaju 3
Bogotá 3
Bremen 3
Cambridge 3
Caratinga 3
Cariacica 3
Fuzhou 3
Houston 3
Lahore 3
Manaus 3
Mineo 3
Nairobi 3
Ningbo 3
Totale 2.541
Salva come PNG Salva come JPEG
Nome #
Diagnostic accuracy of faecal calprotectin in a symptom-based algorithm for early diagnosis of inflammatory bowel disease adjusting for differential verification bias using a Bayesian approach 140
Comparative Efficacy of Vedolizumab and Adalimumab in Ulcerative Colitis Patients Previously Treated With Infliximab 131
Cancer risk in inflammatory bowel disease: a 6-year prospective multicenter nested case-control IG-IBD study 122
Effectiveness and Safety Profiles of Biological Therapies in Inflammatory Bowel Disease: Real Life Data from an Active Pharmacovigilance Project 117
Direct oral anticoagulants increase the risk of anaemia and hospitalization in IBD patients with active intestinal disease 115
Late-onset Crohn's disease: a comparison of disease behaviour and therapy with younger adult patients: the Italian Group for the Study of Inflammatory Bowel Disease 'AGED' study 115
DWI ratios: New indexes for Crohn's disease activity at magnetic resonance enterography? 113
Disease patterns in late-onset ulcerative colitis: Results from the IG-IBD “AGED study” 112
Effectiveness and safety of vedolizumab in a matched cohort of elderly and nonelderly patients with inflammatory bowel disease: The IG-IBD LIVE study 112
Effectiveness of Ustekinumab on Crohn‘s Disease Associated Spondyloarthropathy: Real-World Data from the Sicilian Network for Inflammatory Bowel Diseases (SN-IBD) 110
Outcome in ulcerative colitis after switch from adalimumab/golimumab to infliximab: A multicenter retrospective study 108
A propensity score weighted comparison of Vedolizumab, Adalimumab, and Golimumab in patients with ulcerative colitis 106
Dual Targeted Therapy: a possible option for the management of refractory Inflammatory Bowel Disease 103
Effectiveness and safety of vedolizumab in biologically naïve patients: A real-world multi-centre study 100
Inflammatory Bowel Disease in the Elderly – Knowledge Gaps and Potential Directions in Research 95
Role of IL-33/ST2 Pathway in Inflammatory Bowel Disease: An Overview and Future Perspectives 92
Tissue levels of Tumour Necrosis Factor-alpha as molecular biomarker of inflammation and prediction of sustained treatment response in patients with Ulcerative Colitis. 91
Management of patients with inflammatory bowel disease and outcomes during the first wave of the Covid-19 pandemic 81
Comparison of two strategies for the management of postoperative recurrence in Crohn's disease patients with one clinical risk factor: A multicentre IG-IBD study 80
Prevalence, Pathogenesis and Management of Anemia in Inflammatory Bowel Disease: An IG-IBD Multicenter, Prospective, and Observational Study 80
The PROSIT-BIO Cohort: A Prospective Observational Study of Patients with Inflammatory Bowel Disease Treated with Infliximab Biosimilar 77
One-year effectiveness and safety of ustekinumab in ulcerative colitis: a multicenter real-world study from Italy 77
Stevens-Johnson syndrome on treatment with sulfasalazine for Crohn’s disease: Need for a multidisciplinary approach 76
Telemedicine and Remote Screening for COVID-19 in Inflammatory Bowel Disease Patients: Results from the SoCOVID-19 Survey 75
IL PAZIENTE ANZIANO CON MALATTIA INFIAMMATORIA CRONICA INTESTINALE: OSSERVAZIONI IN UN GRUPPO DI PAZIENTI AMBULATORIALI 75
Quality of Life (QoL) in Patients with Chronic Inflammatory Bowel Diseases: How Much Better with Biological Drugs? 72
The SPOSIB SB2 Sicilian Cohort: Safety and Effectiveness of Infliximab Biosimilar SB2 in Inflammatory Bowel Diseases, Including Multiple Switches 71
A propensity score weighted comparison of vedolizumab and adalimumab in Crohn's disease 69
DWI ratios at MR-Enterography: a new way for inflammation degree assessment in Crohn's disease patients? 67
Effectiveness of adalimumab for ulcerative colitis: A multicentre, retrospective study of clinical practice in Italy 66
Ustekinumab in Crohn's disease: Real-world outcomes from the Sicilian network for inflammatory bowel diseases 66
Activities related to inflammatory bowel disease management during and after the coronavirus disease 2019 lockdown in Italy: How to maintain standards of care 65
A real world investigation on prevalence, clinical features, and therapy of inflammatory bowel disease in the city of Messina, Italy 65
Persistence on Anti-Tumour Necrosis Factor Therapy in Older Patients with Inflammatory Bowel Disease Compared with Younger Patients: Data from the Sicilian Network for Inflammatory Bowel Diseases (SN-IBD) 64
Defense mechanisms and inflammatory bowel diseases: a narrative review 63
Efficacy and Safety of Biological Therapies and JAK Inhibitors in Older Patients with Inflammatory Bowel Disease 62
Objective comparison of vedolizumab and ustekinumab effectiveness in Crohn's disease patients failure to TNF-alpha inhibitors 62
Predictors of Covid-19 vaccination acceptance in IBD patients: a prospective study 60
Portal hypertensive enteropathy: multimodality assessment through computed tomography and magnetic resonance enterography 57
Ultrasonography tight control and monitoring in crohn's disease during different biological therapies: a multicenter study 57
Safety and efficacy of combining biologics or small molecules for inflammatory bowel disease or immune-mediated inflammatory diseases: A European retrospective observational study 56
Incident Colorectal Cancer in Inflammatory Bowel Disease 54
Rates of Adverse Events in Patients With Ulcerative Colitis Undergoing Colectomy During Treatment With Tofacitinib vs Biologics: A Multicenter Observational Study 52
Genetic Polymorphisms on TNFA, TNFRSF1A, and TNFRSF1B Genes Predict the Effectiveness of Anti-TNF-α Treatment in Inflammatory Bowel Disease Patients 52
Ménétrier's disease in a patient with refractory ulcerative colitis: a clinical challenge and review of the literature 50
Follow-up evaluation and management of anemia in inflammatory bowel disease: A study by the Italian Group for Inflammatory Bowel Diseases (IG-IBD) 46
Low Adherence is Associated with Chronic Active Disease in Ulcerative Colitis: A Retrospective Study from a Single Referral Center 45
Two-year effectiveness and safety of golimumab in ulcerative colitis: An IG-IBD study 45
Corticosteroid use in patients with inflammatory bowel diseases: A real-life sub-analysis of the Italian DICE study 43
Mitigating the Risk of Tofacitinib-induced Adverse Events in the Elderly Population with Ulcerative Colitis 42
SPOSAB ABP 501 - A Sicilian Prospective Observational Study of Patients with Inflammatory Bowel Disease Treated with Adalimumab Biosimilar ABP 501 41
null 40
Letter: the clinical course of Crohn's disease—the Sicilian experience 40
Vedolizumab may be an effective option for the treatment of postoperative recurrence of Crohn's disease 36
Epidemiology and clinical course of late onset inflammatory bowel disease 33
null 33
Upadacitinib-Induced Hemolysis in a Patient With Glucose-6-Phosphate Dehydrogenase Deficiency-A Possible Adverse Drug Reaction 28
Safety and effectiveness of tofacitinib in ulcerative colitis: Data from TOFA-UC, a SN-IBD study 28
Ustekinumab is a promising option for the treatment of postoperative recurrence of Crohn's disease 27
Suboptimal disease control and contributing factors in Italian IBD patients: The IBD-PODCAST Study 27
Ulcerative Colitis in Adulthood and in Older Patients: Same Disease, Same Outcome, Same Risks? 26
Standard Therapeutic Approach and New Therapies 22
Severe Activity of Inflammatory Bowel Disease is a Risk Factor for Severe COVID-19 20
The Effectiveness of Risankizumab as Induction Therapy for Crohn's Disease: Data From the Sicilian Network for Inflammatory Bowel Diseases 20
Psychological impairment in inflammatory bowel diseases: the key role of coping and defense mechanisms 20
Vedolizumab in inflammatory bowel disease: Real-world outcomes and their prediction with machine learning-the IG-IBD LIVE study 7
Totale 4.402
Salva come PNG Salva come JPEG
Categoria #
all - tutte 17.905
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 17.905
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202174 0 0 0 0 0 4 18 5 5 19 16 7
2021/2022287 5 31 3 2 8 4 14 10 11 74 21 104
2022/2023597 39 65 26 53 29 45 14 28 268 11 13 6
2023/2024256 20 29 36 54 14 23 7 15 0 33 8 17
2024/20251.244 16 21 16 79 60 76 94 194 271 79 133 205
2025/20261.799 156 145 216 227 339 716 0 0 0 0 0 0
Totale 4.402